Estradiol Patch
Product Images NDC 0378-4622

17 FDA label images from Mylan Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Estradiol (NDC 0378-4622). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Estradiol Structural Formula (Image 01)

Estradiol Structural Formula (Image 01)
Chemical structure of estradiol with an indication of half a water molecule (1/2 H2O) associated, representing the hydrate form.*
FDA Label Image

Estradiol Transdermal System Three Layers (Image 02)

Estradiol Transdermal System Three Layers (Image 02)
An instructional diagram illustrating the three labeled components of a transdermal Estradiol patch: (1) Backing, (2) Adhesive Containing Estradiol, and (3) Oversized Protective Liner. The layers are shown in cross-section with distinct patterns for each component.*
FDA Label Image

Figure 1: Mean Baseline-uncorrected Estradiol Serum Concentration-time Profiles Following A Single Dose Of Estradiol Transdermal System (twice-weekly) 0.1 mg Per Day (treatment A), 0.05 mg Per Day (treatment B), And 0.025 mg Per Day (treatment C) (n = 36) (Image 03)

Figure 1: Mean Baseline-uncorrected Estradiol Serum Concentration-time Profiles Following A Single Dose Of Estradiol Transdermal System (twice-weekly) 0.1 mg Per Day (treatment A), 0.05 mg Per Day (treatment B), And 0.025 mg Per Day (treatment C) (n = 36) (Image 03)
A line graph showing serum estradiol concentration (pg/mL) over time (days) for three dosing levels of estradiol transdermal patch: 0.1 mg/day, 0.05 mg/day, and 0.025 mg/day. The graph illustrates serum concentration rising sharply after application, peaking near day 1, and then gradually declining by day 4 to near baseline.*
FDA Label Image

Figure 2 Mean (sd) Change From Baseline In Mean Daily Number Of Hot Flushes For Vivelle 0.0375 mg Versus Placebo In A 12-week Trial (Image 04)

Figure 2 Mean (sd) Change From Baseline In Mean Daily Number Of Hot Flushes For Vivelle 0.0375 mg Versus Placebo In A 12-week Trial (Image 04)
Bar chart comparing mean (SD) reduction from baseline for Vivelle 0.0375 mg/day estradiol patch versus placebo at weeks 4, 8, and 12. The chart shows greater reduction values for Vivelle compared to placebo at each time point, with sample sizes (n) noted for each group. Asterisks indicate statistically significant differences (p<0.05).*
FDA Label Image

Figure 3: Bone Mineral Density – Ap Lumbar Spine Least Squares Means Of Percentage Change From Baseline All Randomized Women With At Least One Post-baseline Assessment Available With Last Post-baseline Observation Carried Forward (Image 05)

Figure 3: Bone Mineral Density – Ap Lumbar Spine Least Squares Means Of Percentage Change From Baseline All Randomized Women With At Least One Post-baseline Assessment Available With Last Post-baseline Observation Carried Forward (Image 05)
A line graph titled 'Bone mineral density - AP Lumbar spine' showing the least squares means of percentage change from baseline over treatment duration (weeks 26, 52, 78, 104). The graph compares five groups: Estradiol patches at 0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, 0.025 mg/day, and placebo. The y-axis represents percent change from baseline, while the x-axis represents treatment duration in weeks.*
FDA Label Image

Figure 4: Bone Mineral Density – Femoral Neck Least Squares Means Of Percentage Change From Baseline All Randomized Women With At Least One Post-baseline Assessment Available With Last Post-baseline Observation Carried Forward (Image 06)

Figure 4: Bone Mineral Density – Femoral Neck Least Squares Means Of Percentage Change From Baseline All Randomized Women With At Least One Post-baseline Assessment Available With Last Post-baseline Observation Carried Forward (Image 06)
A line graph showing the percentage change from baseline in bone mineral density at the femoral neck over different treatment durations (Weeks 26, 52, 78, and 104). The graph compares four strengths of Vivelle (0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, 0.025 mg/day) and a placebo, with statistical significance annotations for various comparisons over time.*
FDA Label Image

Figure A (Image 07)

Figure A (Image 07)
An illustration showing the packaging components for Estradiol transdermal patches by Mylan Pharmaceuticals Inc. It depicts a carton, a calendar-folded card with product and usage information, a pouch containing a single patch, and prescribing and patient information leaflets.*
FDA Label Image

Figure B (Image 08)

Figure B (Image 08)
An instructional illustration showing a hand writing on a weekly application schedule chart inside the packaging of an Estradiol transdermal patch. The image guides users on how to track patch application days for doses from Mylan Pharmaceuticals Inc.*
FDA Label Image

Figure C (Image 09)

Figure C (Image 09)
An instructional diagram showing hands peeling open the adhesive backing of an Estradiol transdermal patch packet, labeled with the proprietary name Estradiol, multiple strength options, and the Mylan Pharmaceuticals Inc. logo.*
FDA Label Image

Figure D (Image 10)

Figure D (Image 10)
An instructional illustration showing two hands peeling or removing a backing from a single transdermal patch. The image emphasizes the proper handling and removal of the Estradiol transdermal patch from its packaging before application.*
FDA Label Image

Instructions For Use Figures E And F (Image 11)

Instructions For Use Figures E And F (Image 11)
Two black-and-white line drawings labeled Figure E and Figure F show a person applying an estradiol transdermal patch to the lower abdomen area, demonstrating proper placement of the medication patch on the skin.*
FDA Label Image

Figure G (Image 12)

Figure G (Image 12)
Illustration showing the application of a transdermal patch on the lower abdomen. Two images depict a person placing the patch on the left and right sides of the lower abdomen with a hand, indicating possible placement sites for the Estradiol transdermal patch.*
FDA Label Image

Estradiol Transdermal System 0.025 mg/day Carton Label (Image 13)

Estradiol Transdermal System 0.025 mg/day Carton Label (Image 13)
Estradiol 0.025 mg/day transdermal patch carton label from Mylan Pharmaceuticals Inc. The label indicates the product is a transdermal system delivering estradiol twice weekly. The package includes two systems and provides an application schedule reminder. The label also highlights the product is for prescription use and includes instructions on application and storage.*
FDA Label Image

Estradiol Transdermal System 0.0375 mg/day Carton Label (Image 14)

Estradiol Transdermal System 0.0375 mg/day Carton Label (Image 14)
Estradiol 0.0375 mg/day transdermal system patch label by Mylan Pharmaceuticals Inc. The label shows the product name, strength, dosage form, and route. It includes application schedule instructions and product details such as adhesive components, storage conditions, and lot information area. The packaging is designed for a twice-weekly dosing regimen.*
FDA Label Image

Estradiol Transdermal System 0.05 mg/day Carton Label (Image 15)

Estradiol Transdermal System 0.05 mg/day Carton Label (Image 15)
Packaging label for Estradiol Transdermal System USP, 0.05 mg/day strength, delivered twice weekly. The label shows the brand name Estradiol, product strength, dosage form as a patch, and labeler Mylan Pharmaceuticals Inc. Instructions for application schedule and storage are visible, along with regulatory text and barcodes. The label emphasizes usage for transdermal delivery only.*
FDA Label Image

Estradiol Transdermal System 0.075 mg/day Carton Label (Image 16)

Estradiol Transdermal System 0.075 mg/day Carton Label (Image 16)
Estradiol 0.075 mg/day transdermal patch carton, USP, labeled for twice-weekly application. The packaging is from Mylan Pharmaceuticals Inc. and includes an application schedule checklist. The label shows the strength as 0.075 mg/day and states the product is for transdermal use only.*
FDA Label Image

Estradiol Transdermal System 0.1 mg/day Carton Label (Image 17)

Estradiol Transdermal System 0.1 mg/day Carton Label (Image 17)
Packaging label for Estradiol 0.1 mg/day transdermal patch by Mylan Pharmaceuticals Inc. The label specifies this is a twice-weekly patch delivery system and includes application schedule instructions alongside detailed product information and usage warnings. The label highlights that the product is for prescription use only and includes the NDC 0378-4623-26.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.